D. Boral Capital analyst Jason Kolbert downgraded Cero Therapeutics (CERO) to Hold from Buy with no price target Q3 preliminary results highlight capital structure headwinds and the company is delaying its Form 10-Q filing while finalizing accounting related to recent equity transactions, the firm noted as it moved to the sidelines.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO: